India still grapples with the challenge of halting the sale of toxic cough syrup. Despite some notable progress, the World Health Organization (WHO) highlights that much work remains. This concern follows the tragic deaths of at least 24 children. They consumed a domestically-made medicine, Coldrif, manufactured by Sresan Pharma. This incident, therefore, underscores the critical need for robust India cough syrup regulation.
The Coldrif cough medicine was found to contain diethylene glycol, a dangerous toxin. Tests showed quantities nearly 500 times the permissible limit. These recent deaths occurred just two years after global pledges to tighten regulatory systems. Previously, approximately 300 children worldwide died due to similar toxins in syrup-based medicines. Those medicines were made in India and Indonesia.
Improving India’s Cough Syrup Regulation
Enforcement issues persist, according to the WHO. However, India has made some strides. Rutendo Kuwana, WHO team lead for incidents involving substandard and falsified medicines, noted a new Indian rule. This rule requires medicine to be tested for contaminants like diethylene and ethylene glycol before export. This is a positive step forward.
Nevertheless, a significant regulatory gap remains. No such testing rule exists for syrups sold locally within India. The WHO has previously flagged this discrepancy. Kuwana described the situation as a “work in progress,” acknowledging the vastness of India’s pharmaceutical market. It has tens of thousands of manufacturers and many states to oversee. Hence, implementing comprehensive changes takes time.
Future of India Cough Syrup Regulation and Accountability
Reuters reported last week that India plans to scrap its export testing rule. This change would occur once companies upgrade their facilities to international standards by a year-end deadline. India’s health ministry and the Central Drugs Standard Control Organisation (CDSCO) did not comment on these plans. The federal pharmaceuticals regulator also remained silent. Similarly, Sresan Pharma representatives did not respond to repeated inquiries.
A WHO spokesperson welcomed all steps to improve medicine quality. However, concerning the potential dropping of export tests, the spokesperson emphasized thorough testing. The WHO advises manufacturers to test medicines, including raw materials, throughout the entire production process, not just at the final stage. Indian law already mandates testing each batch of raw materials and the final product. Yet, CDSCO stated in October that some firms had not complied with this requirement. The issue of medication safety and regulation is paramount for public health, and a robust understanding of pharmaceuticals is essential. For those looking to deepen their expertise in this critical area, the Certification Course In Safe Prescribing offers valuable insights into ensuring medication safety throughout the healthcare system.
Neighboring countries like Pakistan have attended WHO training sessions on testing for these toxins. Furthermore, the WHO developed a new, cheaper test. Although India did not attend these specific training sessions, it has confirmed to the WHO that it is using this new testing method. Nevertheless, a lack of accountability for previous incidents remains a major disappointment. Despite deaths abroad, authorities in India have not jailed anyone, according to available records. Rutendo Kuwana remarked that this is not merely selling fake shoes. She emphasized that it is a moral issue; if rules are not followed, it becomes criminal due to devastating consequences.
Frequently Asked Questions
Q1: What prompted the WHO’s recent concerns about India’s cough syrup regulation?
The WHO’s concerns were prompted by the deaths of at least 24 children in India. They died after consuming Coldrif cough medicine, made by Sresan Pharma, which contained dangerously high levels of diethylene glycol. This incident highlights ongoing regulatory challenges, especially concerning medications intended for pediatric use. Understanding pediatric health and safety is crucial in preventing such tragedies. Consider exploring the Certification Course In Paediatrics for a comprehensive overview of child health management.
Q2: What progress has India made in addressing toxic cough syrup issues?
India has implemented a new rule. This rule requires medicines to be tested for contaminants like diethylene and ethylene glycol before export. This is a step towards better quality control for exported products.
Q3: What significant regulatory gap has the WHO identified in India?
The WHO has identified a critical regulatory gap. There is no mandatory rule for testing cough syrups sold domestically within India for contaminants. This contrasts with the new export testing requirements, creating a disparity in safety standards.
References
- WHO says India has much to do on toxic cough syrup despite some progress – ETHealthworld
- “Substandard and falsified medical products.” World Health Organization.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.